Loading market dashboard
IQVIA Holdings Inc.
IQVHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
IQVIA Holdings Inc. (IQV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
IQVIA Holdings Inc. (âIQVIAâ) (NYSE: IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the âIssuerâ), intends to raise â¬950,000,000 t
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
VEEV and IQV are benefiting from life sciences digitization trends, but differences in growth, AI adoption and valuation set them apart.
IQVIA's record $34.2B backlog, AI-led pharma demand and $1.24B buybacks support growth despite weak liquidity and no dividend.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IQVIA earns a Buy rating as the market underappreciates its AI-driven Commercial Solutions segment and unique healthcare data assets. AI is a tailwind, not a threat, with 19 of the top 20 pharma companies using IQV's AI agents and workflows. Commercial Solutions segment grew 11.6% year-over-year, outpacing the traditional CRO segment and driving margin expansion.
Our top-performing stocks this quarter were Samsung Electronics, Shell and Lam Research. Our worst contributors were IQVIA, American Express and Heidelberg. We exited our investments in Everest Group and PayPal during the quarter.
Valvoline was Broyhill's largest contributor in the quarter, as the underlying unit economics are intact, while unit growth, service mix, and price continue moving in the same direction. Honeywell management accelerated the aerospace spin-off to the end of June, leaving behind a pure-play automation business that Broyhill believes is worth meaningfully more than the whole. Large pharma is structurally reliant on IQVIA's clinical trial architecture and proprietary data assets, and Broyhill thinks it is highly unlikely that AI can automate away the FDA approval process.
IQVIA Holdings Inc. (IQV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQVIA NYSE: IQV reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing accelerating organic growth across its Commercial Solutions and R&D Solutions businesses, increased demand tied to artificial intelligence offerings and continued strength in forward-looking clinical development metrics.
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
We initiated four new positions in Q1, an above-average pace of activity. We also used the increased volatility to upgrade overall portfolio quality. Our three largest new positions were Amazon.com, Universal Music Group and IQVIA Holdings. In addition to sales of Humana and PayPal, we also exited our positions in social technology leader Meta Platforms and beverages company Diageo.
IQVIA Holdings Inc. (IQV) Q1 2026 Earnings Call Transcript
IQVIA tops on Q1 EPS and revenues on strong Commercial Solutions growth, lifts its 2026 EPS outlook and keeps the revenue & EBITDA guidance steady.
IQVIA Holdings (IQV) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.83 per share. This compares to earnings of $2.7 per share a year ago.
IQV heads into Q1 earnings release with steady growth expectations, driven by AI-backed solutions, strong bookings and rising pharma demand.
Veeva Systems sits at the intersection of life sciences and enterprise cloud computing.
D.A. Davidson and CO. increased its position in IQVIA Holdings Inc. (NYSE: IQV) by 25.4% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,190 shares of the medical research company's stock after acquiring an additional 5,514 shares during the quarter.
Concurrent Investment Advisors LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 36.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,948 shares of the medical research company's stock after purchasing an additional
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arizona State Retirement System reduced its position in IQVIA Holdings Inc. (NYSE: IQV) by 8.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,683 shares of the medical research company's stock after selling 4,548 shares during the quarter.
Calamos Wealth Management LLC acquired a new position in IQVIA Holdings Inc. (NYSE: IQV) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 52,910 shares of the medical research company's stock, valued at approximately $11,926,000. Several other institutional investors and hedge funds
Calamos Advisors LLC boosted its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 268.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 188,707 shares of the medical research company's stock after acquiring an additional 137,441 shares during the period. Calamos Advisors LLC owned
Mirae Asset Global Investments Co. Ltd. increased its position in IQVIA Holdings Inc. (NYSE: IQV) by 27.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,220 shares of the medical research company's stock after acquiring an additional 8,765 shares during the
On April 16, 2026, IQVIA Holdings Inc (IQV) shares fell 3.5% today, bringing the current price to $171.95. Over the past 52 weeks, the stock has fluctuated betw
Artisan Mid Cap Value Fund portfolio trailed the Russell Midcap® Value Index in Q1. Performance was weighed down by a market environment that continued to favor momentum-driven stocks, with less support for quality factors. Among the biggest decliners were ICON, Gartner and Pinterest, each of which dropped by 30% or more during the quarter. Our three largest new buys by position size were Brown & Brown, Veralto and IQVIA Holdings.
Assetmark Inc. grew its position in IQVIA Holdings Inc. (NYSE: IQV) by 33.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 172,625 shares of the medical research company's stock after acquiring an additional 43,436 shares during the quarter.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA's AI push with NVIDIA, strategic deals and buybacks drive growth, but weakening liquidity raises concerns over near-term financial flexibility.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SG Americas Securities LLC grew its stake in IQVIA Holdings Inc. (NYSE: IQV) by 108.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,206 shares of the medical research company's stock after purchasing an additional 26,161 shares during the period.
Eagle Rock Investment Company LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 30.4% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,416 shares of the medical research company's stock after purchasing an additional 14,084 shares during the period.
Shares of IQVIA Holdings Inc. (NYSE: IQV - Get Free Report) have been assigned a consensus rating of "Buy" from the seventeen research firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong
Cullen Investment Group LTD. reduced its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 13.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,941 shares of the medical research company's stock after selling 3,199 shares during the quarter.
Community Trust and Investment Co. trimmed its position in shares of IQVIA Holdings Inc. (NYSE: IQV) by 7.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,312 shares of the medical research company's stock after selling 8,599
Nordea Investment Management AB lessened its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 69.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 713,313 shares of the medical research company's stock after selling 1,600,906 shares during the quarter. Nordea Investment Management AB
Broyhill Asset Management LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 15.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,010 shares of the medical research company's stock after buying an additional 3,560 shares during the
Glenmede Investment Management LP reduced its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 8.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 202,711 shares of the medical research company's stock after selling 19,677 shares during
IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
IQVIA Holdings Inc. (IQV) Presents at Leerink Global Healthcare Conference 2026 Transcript
